PepGen (PEPG) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating
MT NewswiresDec 16, 2024 13:34 ET · Ratings
Leerink Partners Maintains PepGen(PEPG.US) With Buy Rating
Moomoo NewsDec 16, 2024 13:32 ET · Ratings
PepGen Clinical Hold Likely to Be Resolved Quickly, Says Leerink
TipRanksDec 16, 2024 13:20 ET
BofA Securities Downgrades PepGen to Underperform
MT NewswiresDec 16, 2024 12:33 ET
BofA Securities Downgrades PepGen(PEPG.US) to Sell Rating, Cuts Target Price to $3
Moomoo NewsDec 16, 2024 12:32 ET · Ratings
PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold
WSJDec 16, 2024 08:29 ET

Comments

Trytosaveabit

Dec 16, 2024 07:07

Update

$PepGen (PEPG.US)$ Reuters· 7 mins ago
PepGen Announces Clinical Hold in the U.S. on Ind Application to Initiate Connect2-Edo51 Phase 2 Study of Pgn-Edo51 for Duchenne Muscular Dystrophy

Jaguar8

Dec 16, 2024 07:03

NEWS

$PepGen (PEPG.US)$
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
Monday, 16th December at 8:00 am
-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled-
PepGen Inc. (NASDAQ: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular...

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

28

9

7

Jaguar8

Jul 30, 2024 17:12

NEWS: (No Negative Findings) PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

$PepGen (PEPG.US)$
Positive
▪️PGN-EDO51 achieved mean exon skipping levels of 2.15% after three months at 5 mg/kg dose
▪️Mean muscle-adjusted dystrophin level increased by 0.70% from baseline
▪️Mean absolute dystrophin level increased by 0.26% from baseline
▪️The 5 mg/kg dose was well-tolerated with no discontinu...

Trytosaveabit

Jul 30, 2024 16:04

Hmmm? Looks good to me?

$PepGen (PEPG.US)$ Hey Dr @Jaguar8 i need you! Hehehe. What exactly am i missing here??? I dont see it?? ((((. PepGen Shares Data From Low-Dose Cohort Of PGN-EDO51 In Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial For Treatment Of Duchenne Muscular Dystrophy; Says Was Well Tolerated, And All Patients Continued To Long-Term Extension Portion Of Trial. Dosing Of Second Cohort At 10 Mg/kg Is Ongoing
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long...

3

30

PEPG PepGen

Trade Overview

Capital Trend

News

Comments